Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Raludotatug deruxtecan (Primary)
- Indications Ovarian cancer; Renal cell carcinoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 27 Jun 2024 Planned number of patients changed from 140 to 180.
- 27 Jun 2024 Planned End Date changed from 31 Oct 2024 to 30 Nov 2024.
- 27 Jun 2024 Planned primary completion date changed from 31 Oct 2024 to 30 Nov 2024.